deltatrials
Completed PHASE2 INTERVENTIONAL 4-arm NCT02784444

A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH (EMMINENCE)

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602K in Patients With NASH (EMMINENCE™)

Sponsor: Chiltern International Inc.

Conditions NASH - Nonalcoholic Steatohepatitis Non-alcoholic Fatty Liver Disease Non-alcoholic Steatohepatitis
Interventions MSDC-0602K Placebo
Updated 17 times since 2017 Last updated: Aug 28, 2020 Started: Sep 14, 2016 Primary completion: Jun 30, 2019 Completion: Jun 30, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates NASH - Nonalcoholic Steatohepatitis and Non-alcoholic Fatty Liver Disease and is currently completed. Chiltern International Inc. leads this study, which shows 17 recorded versions since 2016 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~May 2017 · 30 days · monthly snapshot~May 2017 – ~Jun 2017 · 31 days · monthly snapshot~Jun 2017 – ~Jul 2017 · 30 days · monthly snapshot~Jul 2017 – ~Nov 2017 · 4 months · monthly snapshot~Nov 2017 – ~Jun 2018 · 7 months · monthly snapshot~Jun 2018 – ~Aug 2019 · 14 months · monthly snapshot~Aug 2019 – ~Sep 2020 · 13 months · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Dec 2022 · 23 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE2

  5. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE2

▶ Show 12 earlier versions

  1. Jan 2021 — Dec 2022 [monthly]

    Completed PHASE2

  2. Oct 2020 — Jan 2021 [monthly]

    Completed PHASE2

  3. Sep 2020 — Oct 2020 [monthly]

    Completed PHASE2

  4. Aug 2019 — Sep 2020 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  5. Jun 2018 — Aug 2019 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  6. Nov 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

  7. Jul 2017 — Nov 2017 [monthly]

    Recruiting PHASE2

  8. Jun 2017 — Jul 2017 [monthly]

    Recruiting PHASE2

  9. May 2017 — Jun 2017 [monthly]

    Recruiting PHASE2

  10. Apr 2017 — May 2017 [monthly]

    Recruiting PHASE2

  11. Feb 2017 — Apr 2017 [monthly]

    Recruiting PHASE2

  12. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Sep 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Chiltern International Inc.
  • Cirius Therapeutics, Inc.
Data source: Cirius Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Arlington, United States , Bastrop, United States , Brooklyn, United States , Chandler, United States , Chula Vista, United States , Dallas, United States , Englewood, United States , Fayetteville, United States , Flowood, United States , Fort Sam Houston, United States and 30 more locations